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ABSTRACT
Purpose: We stud ied  th e  long-term  efficacy and tolerability of nilutam ide, a  nonsteroidal 
antiandrogen, combined w ith  orchiectomy in  patien ts w ith advanced prostate cancer.
M aterials and  M ethods; A large double-blind tria l was done on 457 patien ts random ized to 
receive n ilu tam ide or placebo after orchiectomy.
R esults: A t 8.5 years of followup significant benefits were found for progression and survival in 
favor of p a tien ts  receiving n ilu tam ide and orchiectomy. In  addition, norm alized prostate  specific 
an tigen  levels a t 3 m onths from  the  s ta r t  of therapy  were predictive of good long-term  outcome. 
Moreover, com bined androgen blockade w ith nilutam ide increased the  chance of patien ts having 
norm al p ro sta te  specific an tigen  levels a t 3 m onths. N ilutam ide was well to lerated  in  the  long 
te rm  w ith  no increase in  th e  incidence of drug specific adverse events.
Conclusions: W ith long-term  followup of patien ts w ith advanced prostate cancer, the  combi­
na tion  of n ilu tam ide  and  orchiectomy has significant benefits in  interval to progression and 
im proved survival com pared to orchiectomy and placebo.
K ey  W o rd s : p ro s ta tic  neoplasms, orchiec
Maximal androgen blockade, the addition of an antiandro­
gen to medical or surgical castration, represents a suitable 
improvement compared to castration alone in patients with 
advanced prostate cancer. Although castration leads to dis­
ease regression and, therefore, improved quality of life, pro­
longed survival is not evident.1,2 A possible explanation for 
this fact is that, although castration greatly decreases serum 
testosterone concentrations by approximately 90%, andro­
gens of adrenal origin remain unaffected.3-4 However, the 
combination of an anti androgen plus castration results in 
inhibition of androgens produced from testicular and adrenal 
sources.
The nonsteroidal antiandrogen nilutamide has proved to 
be effective in combination with castration for advanced pros­
tate cancer. Double-blind comparative studies have indicated 
beneficial effects for nilutamide and orchiectomy compared to 
orchiectomy plus placebo with respect to best objective re­
sponse, improvement in metastatic related pain and normal­
ization of tumor markers.1»2»5 In addition, a significantly 
longer interval to objective or subjective progression for the 
nilutamide plus orchiectomy group has been indicated in a 
double-blind study involving more than 400 patients.6 In this 
large study, in which patients were followed for at least 18 
months, a trend towards prolonged survival was also ob­
served. However, this advantage was not statistically signif­
icant even though the study was mature, since at least 50% 
of the patients had progression or died. These findings have 
been supported by a met a-analysis of 7 double-blind studies, 
including 1,056 evaluable patients, that showed statistically 
significant differences in favor of nilutamide and orchiectomy 
for best objective response, improvements in bone pain, levels 
of tumor markers and disease progression.7 The odds of 
death from cancer and from other causes were also decreased 
in the nilutamide combination group but the difference was 
not statistically significant.
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In the largest of the double-blind studies the followup 
currently is approximately 8.5 years,6 and we report on this 
second efficacy and safety analysis. The relationship between 
early normalization of prostate specific antigen (PSA) and 
disease progression in these patients is also examined (pre­
liminary results have been reported previously8) following 
indications that normalization of PSA, rather than simply a 
decrease, is predictive of improvement in the prognosis of 
advanced prostate cancer.9
MATERIALS AND METHODS
A total of 457 patients with stage D2 prostate cancer was 
initially enrolled into this multicenter double-blind placebo 
controlled study. Following orchiectomy the patients were 
randomized to receive 300 mg. nilutamide once daily for 1 
month and then 150 mg. once daily (225) or identical placebo 
tablets (232). During the extended followup clinical and lab­
oratory evaluations6 were repeated every 6 months. Objec­
tive progression was assessed using modified (more strict) 
National Prostatic Cancer Project criteria.
Patients continued taking the study drug or placebo until 
they had objective progression or intolerance, or withdrew 
consent. When progression occurred only patients who had 
been on nilutamide could continue with this drug on an open 
label basis to allow a comparison according to the initial 
randomization. Such patients were included in the safety 
analysis. All patients were followed until death. This sec­
ond analysis was performed on 2 main efficacy criteria: 1) 
intervals to progression and 2) death. Safety was assessed by 
questioning patients in a general manner at each visit to 
determine whether any clinical adverse experience had oc­
curred and by monitoring laboratory values. PSA was meas­
ured at a central laboratory using the Pros-Check* PSA 
radioimmunoassay kit (upper normal value 2.5 ng./ml.) be-
* Yang Laboratories, Inc., Bellevue, Washington.
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fore treatment, at 1, 3 and 6 months after the start of treat­
ment, and then at regular 6-month intervals.
Progression-free and survival actuarial rates were com­
puted with the Kaplan-Meier estimate. The survival distri­
bution of the 2 treatment groups was subjected to the log 
rank test. An intent-to-treat analysis was also performed on 
all patients studied.
RESULTS
Patient and disease characteristics at study entry were 
similar between the 2 groups,6 At the second cutoff date for 
data collection (December 31,1994) followup ranged from 82 
to 102 months, which was 55 months longer than that of the 
previous analysis of progression and 47 months longer than 
that for the previous analysis of survival.6 Of the patients 
283 were withdrawn from the study due to progression (127 
in the nilutamide group versus 156 in the placebo group) and 
70 due to intercurrent or adverse events (42, or 19% versus 
28, or 12%, respectively).
Interval to progression. The progression-free actuarial sur­
vival rates for 8.5 years in evaluable patients were consis­
tently greater in the nilutamide plus orchiectomy group than 
in the placebo plus orchiectomy group (part A  of figure). 
Median intervals to progression were 21.2 and 14.7 months, 
respectively. This 6,5-month difference (44% improvement) 
was statistically significant (p = 0.002). Even after 5 years of 
therapy 20% of patients receiving nilutamide did not have 
progression compared to 12% receiving placebo.
Interval to death. At 8.5 years of followup the median 
intervals to death from prostate cancer were 37.0 and 29.8 
months for patients in the nilutamide plus orchiectomy and 
placebo plus orchiectomy groups, respectively, for a statisti­
cally significant (p = 0.013) difference of 7 months (24% 
increase, part B of figure). At 6 years the survival rates were 
32 and 21%, respectively. When all causes of death for all 
patients were considered the 16% survival gain was still in 
favor of nilutamide plus orchiectomy (p = 0.033, part C of 
figure).
Tolerability. At the initial analysis 102 patients (45%) in 
the nilutamide plus castration and 89 (38%) in the castration 
alone groups had been followed for at least 18 months. After
7 to 8 years of followup 12 (5%) and 6 (2.5%) patients were 
still taking nilutamide or placebo, respectively. After 8.5 
years of treatment the number of patients remaining in the 
study was low and may be seen on actuarial curves for 
progression (number of patients at risk). Despite this longer 
exposure to treatment, no new cases of drug specific adverse 
events were experienced, such as interstitial pneumonitis or 
visual disorder. Moreover, since the initial analysis only 7 
patients from the nilutamide group and 8 from the placebo 
group discontinued treatment due to adverse or intercurrent 
events. Age related intercurrent events, not necessarily lead­
ing to study dropout, occurred with the same incidence in 
both treatment groups.
PSA. PSA levels were measured in 272 of the evaluable 
patients. Regardless of the treatment group, PSA levels were 
elevated in 97% of these patients at baseline. After 3 months 
of treatment PSA normalized in 121 patients (44%) and re­
mained elevated in 151 (56%). No further improvements in 
PSA were observed after 6 months or longer of treatment. 
Patients whose PSA was normal at 3 months had signifi­
cantly longer median intervals to disease progression (p 
<0.0001) and death (p <0.0001) than those with elevated 
PSA at 3 months. Median progression-free intervals were 24 
versus 17 months, respectively, median interval to disease 
related death was 49 versus 28 months, respectively, and 
median interval to death from all causes (overall survival) 
was 37 versus 24 months, respectively (p <0.0001). When 
PSA was analyzed by treatment the percentage of patients 
with normal PSA at 3 months was significantly (p <0.001)
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greater in the nilutamide plus orchiectomy (59%) than in the 
placebo plus orchiectomy (28%) groups.
DISCUSSION
At 8.5 years of followup of patients in a large, double-blind, 
randomized study orchiectomy combined with nilutamide re­
sulted in statistically significant improvements in cancer 
survival (p = 0.013), overall survival (p = 0.033) and interval 
to progression (p = 0.002) compared to orchiectomy plus 
placebo. In an earlier (mature) analysis there was a signifi­
cant difference (p = 0.005) in interval to progression and a 
trend towards improved survival.6 In both analyses the me­
dian interval to death from cancer was 37 months for the 
nilutamide group. However, with prolonged followup the dif­
ference was confirmed and became statistically significant. 
Moreover, the 6.5-month difference in interval to progres­
sion, reported here with extended followup, increased the
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statistical significance found in the previous study (from p =
0.005 to p -  0.002).
It is noteworthy that patients who prematurely discontin­
ued treatm ent because of adverse events were included in the 
analysis of interval to progression and censored at treatment 
discontinuation. Therefore the progression analysis was less 
likely to favor the nilutamide group, since the percentage of 
dropouts for adverse events was slightly greater in the nilu­
tamide (19%) than in the placebo (12%) group. However, even 
with this unfavorable bias, interval to progression was sig­
nificantly longer in the nilutamide group.
The a priori statistical determination of the power of the 
study was made under the assumptions th a t interval to ob­
jective progression for the placebo plus orchiectomy group 
would be 65 weeks and that 200 patients in each treatment 
group would have provided a 94% chance of detecting a 38% 
improvement in the median progression-free survival from 
65 to 90 weeks at the 0.05 level of confidence. These assump­
tions were met and the clear benefit of adding nilutamide to 
castration has been demonstrated.
Nilutamide was generally well tolerated, and most of the 
adverse events reported were consistent with those found 
with other endocrine therapies.6 Moreover, with prolonged 
(8.5 years) exposure to nilutamide there were no increases in 
the incidences of specific adverse events, for example prob­
lems with visual adaptation when changing from a bright 
light to a dark environment and interstitial pneumonitis. In 
the previous analysis visual disturbance was the second most 
frequent adverse event (after hot flushes), affecting 27% of 
patients receiving nilutamide combined with orchiectomy.6 
Visual disturbances are generally mild and tend to disappear 
after the scheduled dosage reduction from 300 to 150 mg., or 
spontaneously, they only lead to approximately 2% of with­
drawals from therapy and are always reversible on treat­
ment discontinuation.2»5»6«10 Interstitial pneumonitis is a 
rare adverse event (1 of 225 patients in our study) and is 
reversible with discontinuation of nilutamide.2»11
An extended followup, as in our study, allows for statistical 
confirmation of earlier trends in efficacy results and for as­
sessment of the long-term safety of combined androgen block­
ade. Our efficacy results reported have followed a pattern 
similar to those for European Organization for Research and 
Treatment of Cancer study No. 30853, in which patients were 
randomized to receive combined androgen blockade (flut- 
amide and a luteinizing hormone-releasing hormone ana­
logue) or orchiectomy.12 In that study a followup of approxi­
mately 5 years indicated maximal androgen blockade to be 
statistically significantly better in terms of progression and 
duration of survival but, again, there had only been a trend 
to increased survival in a previous analysis.13
Statistically significantly longer progression-free and me­
dian survivals have also been reported in a large National 
Cancer Institute study for flutamide and a luteinizing 
hormone-releasing hormone analogue, compared to a lutein­
izing hormone-releasing hormone analogue alone.14 In the 
National Cancer Institute study the benefits for maximal 
androgen blockade were most evident in patients with a good 
performance status and minimal disease. In contrast, other 
generally smaller studies have indicated no improvements in 
survival or interval to disease progression for maximal an­
drogen blockade compared to castration.2>10' 15-18
In our study orchiectomy was chosen rather than luteiniz­
ing hormone-releasing hormone agonists not only to avoid 
any compliance problems relating to the method of castration 
but also to avoid disease flare found in up to 5% of patients 
receiving luteinizing hormone-releasing hormone agonists as 
monotherapy.19 This choice also allows the long-term efficacy 
of the antiandrogen to be related to its self-effect rather than 
to the prevention of disease flare.
Early normalization of PSA was shown to predict an im­
proved long-term response to hormonal treatm ent in terms of
interval to disease progression and death. Nilutamide plus 
orchiectomy increased the chance of a patient having a nor­
mal PSA within 3 months of treatment and, therefore, im­
proved the probability of longer progression-free interval and 
survival. This finding is consistent with the results of a 
previous study of nilutamide and a luteinizing hormone- 
releasing hormone analogue compared to the antiandrogen 
plus placebo, in which gains in median interval to progres­
sion and survival were reported in patients whose PSA nor­
malized by 3 months regardless of the treatment group.20
Nilutamide, with its long plasma elimination half-life (56 
hours), offers the convenience of a once daily dosing regi­
men.21 Although nilutamide was initially used in clinical 
studies in divided doses (every 8 hours), we have shown it to 
be effective and well tolerated as a single daily dose. Once 
daily dosing has obvious benefits in terms of compliance 
rather than 3 or 4 times daily schedules.22 Moreover, compli­
ance is particularly important in the elderly, and prostate 
cancer mainly affects men older than 60 years.23
CONCLUSIONS
The treatment of advanced prostate cancer is still only 
palliative. It is important to delay the progress of the disease 
and, therefore, maintain and/or improve the quality of life 
of patients for as long as possible. The long-term followup of 
patients with advanced prostate cancer has indicated signif­
icant benefits in interval to progression and also survival for 
a combined orchiectomy and nilutamide regimen compared 
to orchiectomy and placebo. Furthermore, the prognostic 
value of monitoring PSA early in therapy has been demon­
strated on the outcome of disease in terms of survival and 
progression, possibly making PSA a surrogate marker of 
efficacy,
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